The effects of repeat omalizumab administration on skin test positivity and the assessment of the safety of administration in patients with positive skin tests to mouse antigen

Allergy and Asthma Proceedings

Volumn 28, Issue 3, 2007, Pages 320-323

  Varghese, Mathew ^a   Lieberman, Phil ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aeroallergen; Anaphylaxis; Immunoglobulin E; Mouse allergy; Mouse epitope; Omalizumab; Skin test reactivity

Indexed keywords

ALLERGEN; MONOCLONAL ANTIBODY; OMALIZUMAB;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ARTICLE; CHEMICALLY INDUCED DISORDER; CHILD; DRUG TOXICITY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOLOGY; INTRACUTANEOUS TEST; MALE; MIDDLE AGED;

ADOLESCENT; ADULT; AGED; ALLERGENS; ANAPHYLAXIS; ANTIBODIES, MONOCLONAL; CHILD; DRUG TOXICITY; HUMANS; HYPERSENSITIVITY, IMMEDIATE; INTRADERMAL TESTS; MALE; MIDDLE AGED;

EID: 34447260290     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: 10.2500/aap.2007.28.3005     Document Type: Article

References (18)

1. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med 164:S1-S5, 2001.
2. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184-190, 2001.
3. Burrows B, Martinez FD, Halonen M, et al. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N Engl J Med 320:271-277, 1989.
4. Lin FJ, Wong D, and Chan-Yeung M. Immediate skin reactivity in adult asthmatic patients. Ann Allergy Asthma Immunol 74:398-404, 1995.
5. Zimmermann J, Silverman R, and Frieri M. Specific IgE levels in moderate to severe asthmatics in the emergency department. Ann Allergy Asthma Immunol 96:P151, 2006.
6. Doan T, and Zeis CR. Skin testing in allergy. Allergy Proc 14:110-111, 1993.
7. Demoly P, Piette V, and Bousquet J. In vivo methods for study of allergy: Skin tests, techniques, and interpretation. In Middleton's Allergy: Principles and Practice, 6th ed. Adkinson NF Jr, Yunginger JW, Busse WW, et al. (Eds). St. Louis: Mosby, Inc., 631-643, 2003.
8. Ong YE, Menzies-Gow A, Barkans J, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116:558-564, 2005.
9. Noga O, Hanf G, and Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 131:46-52, 2003.
10. Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function. J Allergy Clin Immunol 114:527-530, 2004.
11. Togias A, Corren J, Shapiro G, et al. Anti-IgE treatment reduces skin test reactivity. J Allergy Clin Immunol 101(suppl):S171, 1998.
12. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 115:459-465, 2005.
13. Huang Y-C, Leyko B, and Frieri M. Effects of omalizumab and budesonide on markers of inflammation in human bronchial epithelial cells. Ann Allergy Asthma Immunol 95:443-451, 2005.
14. Soresi S, and Togias A. Mechanisms of action of anti-immunoglobulin E therapy. Allergy Asthma Proc 27:S15-S23, 2006.
15. Lanier B. Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Allergy Asthma Proc 27:S37-S42, 2006.
16. Varghese M, Lieberman P, Treadwell G, et al. Omalizumab (O) administration reduces symptom scores, medication use, and markedly diminishes skin tests (ST) reactivity. Ann Allergy Asthma Immunol 94:110, 2005 (Abs 39A).
17. Price K, Woodard L, Pringle M, et al. Anaphylaxis to omalizumab after 14 months of successful therapy. J Allergy Clin Immunol 117:S10, 2006.
18. Price K, and Hamilton R. Anaphylactoid reactions in two patients after omalizumab administration after successful long-term therapy. Allergy Asthma Proc 28:313-319, 2007.